Akari Therapeutics Plc — Director's Dealing 2015

Jan 2, 2015

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Celsus Therapeutics Plc. (CLTX)
CIK: 0001541157
Period of Report: 2015-01-01

Reporting Person: SIDRANSKY DAVID (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	54732	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Options to Purchase Ordinary Shares	$	2017-08-28	Ordinary Shares (68250)		Direct
Options to Purchase Ordinary Shares	$	2018-02-05	Ordinary Shares (60227)		Direct
Options to Purchase Ordinary Shares	$1.56	2022-03-19	Ordinary Shares (25000)		Direct
Options to Purchase Ordinary Shares	$1.56	2022-06-20	Ordinary Shares (30000)		Direct
Options to Purchase Ordinary Shares	$2.00	2023-04-29	Ordinary Shares (100000)		Direct
Options to Purchase Ordinary Shares	$0.75	2024-02-05	Ordinary Shares (45000)		Direct
Options to Purchase Ordinary Shares	$0.60	2024-07-22	Ordinary Shares (45000)		Direct
Warrants to Purchase Ordinary Shares	$2.00	2017-02-12	Ordinary Shares (12500)		Direct

Footnotes

F1: 50% of shares underlying the options vested on 8/28/2008 and the remaining 50% of shares underlying the options vested on 8/28/2009.

F2: 100% of the shares underlying the options vested on 2/5/2008.

F3: 100% of the shares underlying the options vested on 3/19/2013.

F4: 100% of the shares underlying the options vested on 6/20/2012.

F5: 1/3 of the shares underlying the options vest annually, beginning on 4/26/2014.

F6: 100% of the shares underlying the options vested on 5/31/2014.

F7: 100% of the shares underlying the options will vest on 6/1/2015.

F8: 100% of the shares underlying the warrants vested on 2/12/2012.

F9: The exercise price for these options to purchase ordinary shares is 0.80 pound sterling.

F10: The exercise price for these options to purchase ordinary shares is 0.79 pound sterling.